Legend Biotech Corporation (LEGN)
NASDAQ: LEGN · Real-Time Price · USD
31.75
+0.23 (0.73%)
Jun 9, 2026, 1:14 PM EDT - Market open
Legend Biotech Employees
Legend Biotech had 2,965 employees as of December 31, 2025. The number of employees increased by 356 or 13.65% compared to the previous year.
Employees
2,965
Change (1Y)
356
Growth (1Y)
13.65%
Revenue / Employee
$384,148
Profits / Employee
-$84,351
Market Cap
5.90B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 2,965 | 356 | 13.65% |
| Dec 31, 2024 | 2,609 | 783 | 42.88% |
| Dec 31, 2023 | 1,826 | 436 | 31.37% |
| Dec 31, 2022 | 1,390 | 319 | 29.79% |
| Dec 31, 2021 | 1,071 | 189 | 21.43% |
| Dec 31, 2020 | 882 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| PTC Therapeutics | 991 |
| Mirum Pharmaceuticals | 418 |
| Rhythm Pharmaceuticals | 414 |
| TG Therapeutics | 399 |
| Immunovant | 315 |
| Apogee Therapeutics | 261 |
| Kymera Therapeutics | 253 |
| Protagonist Therapeutics | 131 |
LEGN News
- 6 days ago - Legend Biotech price target raised to $49 from $31 at UBS - TheFly
- 6 days ago - Legend Biotech price target raised to $65 from $50 at H.C. Wainwright - TheFly
- 7 days ago - This Is Why Legend Biotech Stock (LEGN) Was Up Today - TipRanks
- 7 days ago - Legend Biotech rises 29.5% - TheFly
- 7 days ago - Legend Biotech presents preliminary clinical data for LB2501 at EHA Congress - TheFly
- 7 days ago - Legend's experimental cell therapy shows promise in blood cancer patients - Reuters
- 7 days ago - Legend Biotech Announces Late-Breaking Oral Presentation at EHA 2026 Showcasing Initial Phase 1 In Vivo CAR-T Data with LB2501 in Non-Hodgkin Lymphoma (NHL) - GlobeNewsWire
- 8 days ago - Legend Biotech presents first-in-human LB2102 results in solid tumors - TheFly